Serological assessment of the durability of vaccine-mediated protection against SARS-CoV-2 infection

References

• Tandon R, Mitra D, Sharma P, McCandless MG, Stray SJ, Bates JT, Marshall GD. Effective screening of SARS-CoV-2 neutralizing antibodies in patient serum using lentivirus particles pseudotyped with SARS-CoV-2 spike glycoprotein. Sci Rep. 2020;10(1):19076. doi:10.1038/s41598-020-76135-w.
   PubMed Web of Science ®Google Scholar
• Congrave-Wilson Z, Cheng WA, Lee Y, Perez S, Turner L, Marentes Ruiz CJ, Mendieta S, Skura A, Jumarang J, Del Valle J. et al. Twelve-month longitudinal serology in SARS-CoV-2 Naïve and experienced vaccine recipients and unvaccinated COVID-19-Infected individuals. Vaccines (Basel). 2022;10(5):10. doi:10.3390/vaccines10050813.
   Web of Science ®Google Scholar
• Dieckhaus KD, Kim MJ, Shen JB, Liang TS, Kleinberg MJ, Siedlarz KM, Banach DB, Metersky ML, Fuller RP, Mortensen EM. et al. SARS-CoV-2 antibody dynamics in healthcare workers after mRNA vaccination. Vaccines (Basel). 2023;11(2):11. doi:10.3390/vaccines11020358.
   Web of Science ®Google Scholar
• Menon V, Shariff MA, Perez Gutierrez V, Carreno JM, Yu B, Jawed M, Gossai M, Valdez E, Pillai A, Venugopal U. et al. Longitudinal humoral antibody response to SARS-CoV-2 infection among healthcare workers in a New York City hospital. BMJ Open. 2021;11(10):e051045. doi:10.1136/bmjopen-2021-051045.
   PubMed Web of Science ®Google Scholar
• Planas D, Staropoli I, Porot F, Guivel-Benhassine F, Handala L, Prot M, Bolland WH, Puech J, Pere H, Veyer D. et al. Duration of BA.5 neutralization in sera and nasal swabs from SARS-CoV-2 vaccinated individuals, with or without omicron breakthrough infection. Med. 2022;3(12):838–47 e3. doi:10.1016/j.medj.2022.09.010.
   PubMedGoogle Scholar
• Gromowski GD, Cincotta CM, Mayer S, King J, Swafford I, McCracken MK, Coleman D, Enoch J, Storme C, Darden J. et al. Humoral immune responses associated with control of SARS-CoV-2 breakthrough infections in a vaccinated US military population. EBioMedicine. 2023;94:104683. doi:10.1016/j.ebiom.2023.104683.
   PubMed Web of Science ®Google Scholar
• de Boer J, Saade U, Granjon E, Trouillet-Assant S, Saade C, Pottel H, Zrein M, Ser Study g C, Nasrallah GK. A novel assessment method for COVID-19 humoral immunity duration using serial measurements in naturally infected and vaccinated subjects. PLoS One. 2022;17(9):e0274553. doi:10.1371/journal.pone.0274553.
   PubMed Web of Science ®Google Scholar
• Dobano C, Ramirez-Morros A, Alonso S, Ruiz-Olalla G, Rubio R, Vidal M, Prados de la Torre E, Jairoce C, Mitchell RA, Barrios D. et al. Eleven-month longitudinal study of antibodies in SARS-CoV-2 exposed and naïve primary health care workers upon COVID-19 vaccination. Immunology. 2022;167(4):528–7. doi:10.1111/imm.13551.
   PubMed Web of Science ®Google Scholar
• Arunachalam PS, Lai L, Samaha H, Feng Y, Hu M, Hui HS, Wali B, Ellis M, Davis-Gardner ME, Huerta C. et al. Durability of immune responses to mRNA booster vaccination against COVID-19. J Clin Invest. 2023;133(10):133. doi:10.1172/JCI167955.
   Web of Science ®Google Scholar
• Kusunoki H, Ohkusa M, Iida R, Saito A, Kawahara M, Ekawa K, Kato N, Yamasaki K, Motone M, Shimizu H. Longitudinal changes in IgG-type SARS-CoV-2 antibody titers after COVID-19 vaccination and a prominent increase in antibody titers when infected after vaccination. Vaccines (Basel). 2023;11(4):11. doi:10.3390/vaccines11040860.
   Web of Science ®Google Scholar
• Follmann D, Janes HE, Buhule OD, Zhou H, Girard B, Marks K, Kotloff K, Desjardins M, Corey L, Neuzil KM. et al. Antinucleocapsid antibodies after SARS-CoV-2 infection in the blinded phase of the randomized, placebo-controlled mRNA-1273 COVID-19 vaccine efficacy clinical trial. Ann Intern Med. 2022;175(9):1258–65. doi:10.7326/M22-1300.
   PubMed Web of Science ®Google Scholar
• Dai YC, Lin YC, Ching LL, Tseng AC, Qin Y, Nerurkar VR, Wang WK. Identification of severe acute respiratory syndrome coronavirus 2 breakthrough infections by anti-nucleocapsid antibody among fully vaccinated non-healthcare workers during the transition from the delta to omicron wave. Front Med. 2022;9:1019490. doi:10.3389/fmed.2022.1019490.
   Web of Science ®Google Scholar
• Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol. 2010;17(7):1055–65. doi:10.1128/CVI.00131-10.
   PubMed Web of Science ®Google Scholar
• Plotkin SA. Recent updates on correlates of vaccine-induced protection. Front Immunol. 2022;13:1081107. doi:10.3389/fimmu.2022.1081107.
   PubMed Web of Science ®Google Scholar
• Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Subbarao K, Kent SJ, Triccas JA, Davenport MP. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205–11. doi:10.1038/s41591-021-01377-8.
   PubMed Web of Science ®Google Scholar
• Fong Y, McDermott AB, Benkeser D, Roels S, Stieh DJ, Vandebosch A, Le Gars M, Van Roey GA, Houchens CR, Martins K. et al. Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial. Nat Microbiol. 2022;7:1996–2010. doi:10.1038/s41564-022-01262-1.
   PubMed Web of Science ®Google Scholar
• Gilbert PB, Montefiori DC, McDermott AB, Fong Y, Benkeser D, Deng W, Zhou H, Houchens CR, Martins K, Jayashankar L. et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. 2022;375:43–50. doi:10.1126/science.abm3425.
   PubMed Web of Science ®Google Scholar
• Yoshida M, Masuda A, Kuo TT, Kobayashi K, Claypool SM, Takagawa T, Kutsumi H, Azuma T, Lencer WI, Blumberg RS. IgG transport across mucosal barriers by neonatal Fc receptor for IgG and mucosal immunity. Springer Semin Immunopathol. 2006;28(4):397–403. doi:10.1007/s00281-006-0054-z.
   PubMed Web of Science ®Google Scholar
• Spiekermann GM, Finn PW, Ward ES, Dumont J, Dickinson BL, Blumberg RS, Lencer WI. Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life: functional expression of FcRn in the mammalian lung. J Exp Med. 2002;196(3):303–10. doi:10.1084/jem.20020400.
   PubMed Web of Science ®Google Scholar
• Bradburne AF, Bynoe ML, Tyrrell DA. Effects of a “new” human respiratory virus in volunteers. British Med J. 1967;3(5568):767–9. doi:10.1136/bmj.3.5568.767.
   PubMed Web of Science ®Google Scholar
• Arieta CM, Xie YJ, Rothenberg DA, Diao H, Harjanto D, Meda S, Marquart K, Koenitzer B, Sciuto TE, Lobo A. et al. The T-cell-directed vaccine BNT162b4 encoding conserved non-spike antigens protects animals from severe SARS-CoV-2 infection. Cell. 2023;186(11):2392–409 e21. doi:10.1016/j.cell.2023.04.007.
   PubMed Web of Science ®Google Scholar